Prices, affordability and utilization pattern of hypertension and diabetes medications in Bangladesh
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Hypertension and diabetes are the leading Non-Communicable Diseases (NCDs) in South Asia, yet the utilization and affordability of essential medicines in community settings remains poorly understood. This community-based cross-sectional study examined the utilization patterns, out-of-pocket costs, and affordability of essential hypertension and diabetes medications in Bangladesh. Methods We conducted a community based cross-sectional survey among adults aged 40 years and older across all eight administrative divisions of Bangladesh. Eligible participants were those currently receiving pharmacological treatment for hypertension, diabetes, or both, and resided within 5 km radius of a primary, secondary, or tertiary health facility. Following written informed consent, data on participants age, sex, socioeconomic status (SES), medicine utilization, treatment costs, and financial coping strategies were collected through structured face-to-face interviews. Affordability was quantified using the World Health Organization–Health Action International (WHO–HAI) methodology, which compared medicine costs against the daily wage of the lowest-paid, unskilled government worker. Finally, medicine prices collected in 2019 were adjusted to 2025 values utilizing the Bangladesh Bureau of Statistics Health Consumer Price Index (BBS Health CPI). Results This study enrolled 353 participants between November 2019 and January 2020 with a mean age 53 years [SD 13] and 69.7% were female. Of them, 57.1% had hypertension, 22.1% had diabetes, and 20.9% had both of the conditions, and their diseases conditions were more frequently diagnosed at a private facility (57.8%), followed by a government facility (29.7%) and a medicine seller (9.1%). A total of fifty one antihypertensive generics were identified across thirteen pharmacological classes, the most commonly used were beta-blockers (29.1%), angiotensin II receptor blockers (21.7%), and calcium channel blocker–beta-blocker combinations (18.1%). A total of 26 antidiabetic generics identified across seven pharmacological classes, sulphonylureas (44.3%), biguanides (39.3%), and insulin (27.1%) were the most frequently prescribed. The proportion of affordable antihypertensive medicine options (< 1 day’s wage) decreased from 62.7% in 2019 to 37.3% in 2025. Similarly, Affordable oral antidiabetic options decreased from 27.7% in 2019 to 5.5%in 2025, leaving Metformin 500 mg as the sole affordable option (0.98 day’s wages). No insulin formulation was affordable in either year; on average, a monthly insulin supply required 6.00 days’ wages in 2019 and 9.53 days’ wages in 2025. The mean monthly medicine expenditure for the patients managing comorbidity of hypertension and diabetes was$8.6, which was three times higher than the expenditure for hypertension alone ($2.9) and 1.6 times higher than that for diabetes alone ($5.3). Spousal savings (40.3%) and adult children support (40.2%) were the most prevalent sources of assistance. Notably, patients from lower socioeconomic strata were more likely to adopt adverse coping behaviors, such as dietary modification or increased working hours, than their higher socioeconomic counterparts (55.6% vs. 35.4%; p = 0.008). Conclusion These findings reveal critical gaps in equitable NCD management, underscoring the urgent need to prioritize generic prescribing aligned with a national treatment protocol. Futhermore, implementing subsidized medicine supplies at primary healthcare facilities is imperative to improve affordability and advance universal health coverage.
Source: BMC Public Health
Language: English
Field: Medicine
Domain: Health Sciences
Keywords: hypertension, diabetes mellitus, drug affordability, out-of-pocket costs, non-communicable diseases, generic drugs, insulin affordability, antihypertensive drugs, antidiabetic drugs, medication use patterns, Bangladesh, socioeconomic status, primary care, antidiabetic drug combination, combination antihypertensive therapy
Open Access status: gold
Estimated APC paid: $3,290
OpenAlex ID: W7161047188
